Clinical trial · Interventional
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
Multicentre Phase II Study Of Concomitant Radio-Chemotherapy Associating Continuous Infusion 5-FU With Hydroxyuree Via Bone Marrow With Or Without Paclitaxel In Treatment Of Inoperable Epidermoid Carcinoma Of Esophagus
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase I/II trial to study the effectiveness of combination chemotherapy with or without paclitaxel combined with radiation therapy in treating patients who have stage II or stage III cancer of the esophagus.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| hydroxyurea | Drug | Hydroxyurea | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed stage II (T2 or T3, N0, M0) or III (T3, N1, M0) epidermoid carcinoma of the esophagus * Inoperable due to initial extension or inoperable with no extension * No visceral metastases * No extension to the tracheo-bronchial pathway * No tracheo-esophageal fistula * No broncho-esophageal fistula * No suspected respiratory mucosal involvement on bronchoscopy * No carcinoma in situ PATIENT CHARACTERISTICS: Age: * 18 to 80 Performance status: * ECOG 0-2 Life expectancy: * Not specified Hematopoietic: * Platelet count at least 120,000/mm\^3 * Hemoglobin at least 10 g/dL * Neutrophil count at least 1,500/mm\^3 * Lymphocyte count at least 1,000/mm\^3 Hepatic: * SGOT and SGPT no greater than 2 times normal * Albumin at least 3.0 g/dL Renal: * Creatinine no greater than 1.4 mg/dL * Calcium less than 11.2 mg/dL Pulmonary: * See Disease Characteristics * No severe respiratory illness (e.g., severe broncho-pathway obstruction or insufficient respiration) * No uncontrolled broncho-pulmonary infection Other: * No other prior history of malignancy except curatively treated carcinoma in situ of the colon or skin cancer * No contraindication to fluorouracil * Not pregnant or nursing * Fertile patients must use effective contraception * No psychiatric illness * HIV negative * Total protein at least 65% of normal PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior biologic therapy Chemotherapy: * No prior chemotherapy Endocrine therapy: * No prior endocrine therapy Radiotherapy: * No prior radiotherapy Surgery: * See Disease Characteristics Other: * No concurrent participation in other study
References
Publications (0)
Data not yet available